Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Uveal Melanoma × tislelizumab × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Renal Cell 3 Stomach Neoplasms 2 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Testicular Germ Cell Tumor 1 Squamous Cell Carcinoma of Head and Neck 1 Skin Neoplasms 1 Sarcoma 1 Recurrence 1 Mesothelioma 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, T-Cell 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma 1 Immunoblastic Lymphadenopathy 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Ipilimumab 25 Nivolumab 19 pembrolizumab 11 incomplete Freund's adjuvant 10 Melphalan 9 Cyclophosphamide 9 Interleukin-2 8 sargramostim 7 MART-1 Antigen 7 CTLA-4 Antigen 7 tebentafusp 6 Temozolomide 6 Ranibizumab 6 montanide ISA 51 5 Sunitinib 5 Radiosurgery 5 Dacarbazine 5 Blood Specimen Collection 5 aldesleukin 4 aflibercept 4 Surveys and Questionnaires 4 Magnetic Resonance Spectroscopy 4 Carboplatin 4 Biopsy 4 Bevacizumab 4 trametinib 3 sotrastaurin 3 fludarabine phosphate 3 fludarabine 3 binimetinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05542342 2025-05-14

SITISVEAL

Grupo Español Multidisciplinar de Melanoma

Phase 2 Completed

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡